Carey RM, et al. - Researchers analyzed data from 4,158 hypertensive individuals taking antihypertensive treatments in the 2009-2014 National Health and Nutrition Examination Survey to compare the prevalence rates of apparent treatment-resistant hypertension (aTRH) among US adults per the 2018 and 2008 American Heart Association Scientific Statements. They found only modestly higher prevalence of aTRH using the definition in the 2018 vs 2008 resistant hypertension Scientific Statement (19.7% vs 17.7%, respectively). An angiotensin-converting enzyme inhibitor, β-blocker, and thiazide diuretic were the most common triple-drug combination taken. Based on the 2018 definition, a thiazide-like diuretic (chlorthalidone or indapamide) was taken by 3.2% of US adults with aTRH and 9.0% were taking a mineralocorticoid receptor blocker (spironolactone or eplerenone).